Story · Medicine & Biotech

STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke

4 outlets · first reported by STAT News 2d ago · latest 1d ago · 22 hours of coverage · 3 countries

Coverage, in order

  1. 2d ago
    first STAT News indie
    STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke

    The Food and Drug Administration on Monday approved Bayer’s drug to reduce recurrence of stroke, making available the first in a novel class of medications that hold the promise of preventing blood clots more safely. Many blood thinners aren’t used in this setting due to their increased risk of…

  2. 1d ago
  3. 1d ago
    Pharmaphorum UK indie
    Bayer bags FDA green light for stroke drug Sunharbo

    Bayer bags FDA green light for stroke drug Sunharbo Phil.Taylor Tue, 10/11/2026 - 09:36

  4. 1d ago
    MedCity News indie study
    FDA Approves First-in-Class Bayer Drug for Reducing the Risk of Stroke

    Bayer’s asundexian, brand name Sunharbo, is the first FDA-approved drug in a new class cardiovascular medicines Approval of the once-daily pill covers secondary stroke prevention in adults.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.